HC Wainwright Analysts Increase Earnings Estimates for CRBU

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities researchers at HC Wainwright lifted their Q3 2026 earnings estimates for Caribou Biosciences in a research note issued to investors on Thursday, October 8th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.25) per share for the quarter, up from their prior estimate of ($0.32). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.07) per share. HC Wainwright also issued estimates for Caribou Biosciences’ Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.04) EPS and FY2027 earnings at ($0.32) EPS.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.08. Caribou Biosciences had a negative net margin of 1,030.42% and a negative return on equity of 89.11%. The firm had revenue of $1.50 million during the quarter, compared to analysts’ expectations of $2.28 million.

Other equities research analysts have also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Caribou Biosciences in a report on Friday, July 17th. Royal Bank Of Canada cut Caribou Biosciences from an “outperform” rating to a “sector perform” rating and set a $1.00 price target for the company. in a report on Wednesday, October 7th. Bank of America lowered their price target on Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. Wall Street Zen downgraded Caribou Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Finally, Brookline Capital Markets lowered Caribou Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $5.50.

Caribou Biosciences Price Performance

Caribou Biosciences stock opened at $0.50 on Monday. The firm has a market capitalization of $53.27 million, a PE ratio of -0.46 and a beta of 2.31. The company’s 50-day moving average is $1.39 and its 200-day moving average is $1.72. Caribou Biosciences has a fifty-two week low of $0.44 and a fifty-two week high of $3.54.

Hedge Funds Weigh In On Caribou Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CRBU. CTC Alternative Strategies Ltd. bought a new position in Caribou Biosciences in the 1st quarter valued at about $29,000. Next Capital Management LLC acquired a new position in shares of Caribou Biosciences in the 2nd quarter valued at approximately $35,000. Westmount Partners LLC bought a new stake in shares of Caribou Biosciences during the 1st quarter worth approximately $37,000. The Manufacturers Life Insurance Company bought a new stake in shares of Caribou Biosciences during the 2nd quarter worth approximately $41,000. Finally, Spark Investment Management LLC bought a new stake in shares of Caribou Biosciences during the 2nd quarter worth approximately $42,000. 77.51% of the stock is owned by institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou’s research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA.